Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study.
Humans
Female
Male
Prospective Studies
Middle Aged
Risk Assessment
Cardiovascular Diseases
/ mortality
Biomarkers
/ blood
Hypertension
/ blood
Cause of Death
Nutrition Surveys
Time Factors
Adult
United States
/ epidemiology
Aged
Apolipoprotein B-100
/ blood
Prognosis
Risk Factors
Blood Pressure
Heart Disease Risk Factors
Apolipoproteins B
/ blood
All-cause mortality
Apolipoprotein B
Cardiovascular disease
Mortality
National Health and Nutrition Examination Survey
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
received:
19
10
2023
accepted:
20
05
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
24
5
2024
Statut:
epublish
Résumé
Dyslipidemia frequently coexists with hypertension in the population. Apolipoprotein B (ApoB) is increasingly considered a more potent predictor of cardiovascular disease (CVD). Abnormal levels of serum ApoB can potentially impact the mortality risk. The prospective cohort study employed data from the National Health and Nutrition Examination Survey (NHANES), which was performed between 2005 and 2016, with follow-ups extended until December 2019. Serum ApoB concentrations were quantified using nephelometry. In line with the NHANES descriptions and recommendations, the reference ranges for ApoB concentrations are 55-140 and 55-125 mg/dL for men and women, respectively. Participants were categorized into low, normal, and high ApoB levels. The low and high groups were combined into the abnormal group. In this study, all-cause mortality (ACM) and CVD mortality (CVM) were the endpoints. Survey-weighted cox hazards models were used for evaluating the correlation between serum ApoB levels and ACM and CVM. A generalized additive model (GAM) was employed to examine the dose-dependent relationship between ApoB levels and mortality risk. After a median of 95 (interquartile range: 62-135) months of follow-up, 986 all-cause and 286 CVD deaths were recorded. The abnormal ApoB group exhibited a trend toward an elevated risk of ACM in relative to the normal group (HR 1.22, 95% CI: 0.96-1.53). The risk of CVM was elevated by 76% in the ApoB abnormal group (HR 1.76, 95% CI: 1.28-2.42). According to the GAM, there existed a nonlinear association between serum ApoB levels and ACM (P = 0.005) and CVM (P = 0.009). In the US hypertensive population, serum Apo B levels were U-shaped and correlated with ACM and CVM risk, with the lowest risk at 100 mg/dL. Importantly, abnormal Apo B levels were related to an elevated risk of ACM and CVM. These risks were especially high at lower Apo B levels. The obtained findings emphasize the importance of maintaining appropriate Apo B levels to prevent adverse outcomes in hypertensive individuals.
Sections du résumé
BACKGROUND
BACKGROUND
Dyslipidemia frequently coexists with hypertension in the population. Apolipoprotein B (ApoB) is increasingly considered a more potent predictor of cardiovascular disease (CVD). Abnormal levels of serum ApoB can potentially impact the mortality risk.
METHODS
METHODS
The prospective cohort study employed data from the National Health and Nutrition Examination Survey (NHANES), which was performed between 2005 and 2016, with follow-ups extended until December 2019. Serum ApoB concentrations were quantified using nephelometry. In line with the NHANES descriptions and recommendations, the reference ranges for ApoB concentrations are 55-140 and 55-125 mg/dL for men and women, respectively. Participants were categorized into low, normal, and high ApoB levels. The low and high groups were combined into the abnormal group. In this study, all-cause mortality (ACM) and CVD mortality (CVM) were the endpoints. Survey-weighted cox hazards models were used for evaluating the correlation between serum ApoB levels and ACM and CVM. A generalized additive model (GAM) was employed to examine the dose-dependent relationship between ApoB levels and mortality risk.
RESULTS
RESULTS
After a median of 95 (interquartile range: 62-135) months of follow-up, 986 all-cause and 286 CVD deaths were recorded. The abnormal ApoB group exhibited a trend toward an elevated risk of ACM in relative to the normal group (HR 1.22, 95% CI: 0.96-1.53). The risk of CVM was elevated by 76% in the ApoB abnormal group (HR 1.76, 95% CI: 1.28-2.42). According to the GAM, there existed a nonlinear association between serum ApoB levels and ACM (P = 0.005) and CVM (P = 0.009).
CONCLUSIONS
CONCLUSIONS
In the US hypertensive population, serum Apo B levels were U-shaped and correlated with ACM and CVM risk, with the lowest risk at 100 mg/dL. Importantly, abnormal Apo B levels were related to an elevated risk of ACM and CVM. These risks were especially high at lower Apo B levels. The obtained findings emphasize the importance of maintaining appropriate Apo B levels to prevent adverse outcomes in hypertensive individuals.
Identifiants
pubmed: 38789961
doi: 10.1186/s12872-024-03949-1
pii: 10.1186/s12872-024-03949-1
doi:
Substances chimiques
Biomarkers
0
APOB protein, human
0
Apolipoprotein B-100
0
Apolipoproteins B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273Informations de copyright
© 2024. The Author(s).
Références
Gianfredi V, Dinu M, Nucci D, Eussen SJPM, Amerio A, Schram MT, Schaper N, Odone A. Association between dietary patterns and depression: an umbrella review of meta-analyses of observational studies and intervention trials. Nutr Rev. 2023;81:346–59.
doi: 10.1093/nutrit/nuac058
pubmed: 36240456
Sander GE, Giles TD. Hypertension and lipids: lipid factors in the hypertension syndrome. Curr Hypertens Rep. 2002;4:458–63.
doi: 10.1007/s11906-002-0026-1
pubmed: 12419175
Poulter N. Coronary heart disease is a multifactorial disease. Am J Hypertens. 1999;12:92S-95S.
doi: 10.1016/S0895-7061(99)00163-6
pubmed: 10555607
Heron M. Deaths: Leading Causes for 2017. Natl Vital Stat Rep. 2019;68:1–77.
pubmed: 32501203
World Health Organization. Hypertension fact sheet. 2019. https://www.who.int/news-room/fact-sheets/detail/hypertension . Accessed 10 June 2023.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
doi: 10.1016/S0140-6736(04)17018-9
pubmed: 15364185
Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension. 2006;47:45–50.
doi: 10.1161/01.HYP.0000196306.42418.0e
pubmed: 16344375
Otsuka T, Takada H, Nishiyama Y, Kodani E, Saiki Y, Kato K, Kawada T. Dyslipidemia and the Risk of Developing Hypertension in a Working-Age Male Population. J Am Heart Assoc. 2016;5:e003053.
doi: 10.1161/JAHA.115.003053
pubmed: 27016576
pmcid: 4943276
Chen S, Cheng W. Relationship Between Lipid Profiles and Hypertension: A Cross-Sectional Study of 62,957 Chinese Adult Males. Front Public Health. 2022;10:895499.
doi: 10.3389/fpubh.2022.895499
pubmed: 35664125
pmcid: 9159857
Cheng W, Zhuang J, Chen S. Dyslipidemia and the Prevalence of Hypertension: A Cross-Sectional Study Based on Chinese Adults Without Type 2 Diabetes Mellitus. Front Cardiovasc Med. 2022;9:938363.
doi: 10.3389/fcvm.2022.938363
pubmed: 35872884
pmcid: 9300889
Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen M-R, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313–30.
doi: 10.1093/eurheartj/ehz962
pubmed: 32052833
pmcid: 7308544
Webb RJ, Mazidi M, Lip GYH, Kengne AP, Banach M, Davies IG. The role of adiposity, diet and inflammation on the discordance between LDL-C and apolipoprotein B. Nutr Metab Cardiovasc Dis. 2022;32:605–15.
doi: 10.1016/j.numecd.2021.12.004
pubmed: 35123856
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, JR, Sperling L, Virani SS, Yeboah J,. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.
pubmed: 30586774
Fischer K, Kassem L. Apolipoprotein B: An essential cholesterol metric for atherosclerotic cardiovascular disease. Am J Health Syst Pharm. 2023;80:83–6.
doi: 10.1093/ajhp/zxac287
pubmed: 36198096
CDC. The National Health and Nutritional Examination Survey (NHANES) Analytic and Reporting Guidelines. Atlanta: GA, CDC; 2006.
CDC. NHANES Laboratory/Medical Technologists Procedures Manual. Atlanta: GA, CDC; 2001.
ALHarthi SSY, Natto ZS, Midle JB, Gyurko R, O’Neill R, Steffensen B,. Association between time since quitting smoking and periodontitis in former smokers in the National Health and Nutrition Examination Surveys (NHANES) 2009 to 2012. J Periodontol. 2019;90:16–25.
doi: 10.1002/JPER.18-0183
pubmed: 30102767
Hicks CW, Wang D, Matsushita K, Windham BG, Selvin E. Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in US Adults: A Prospective Cohort Study. Ann Intern Med. 2021;174:167–74.
doi: 10.7326/M20-1340
pubmed: 33284680
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, de Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglu L, Wiklund O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.
doi: 10.1093/eurheartj/ehz455
pubmed: 31504418
Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4:1287–95.
doi: 10.1001/jamacardio.2019.3780
pubmed: 31642874
pmcid: 7369156
Bittner V. Apolipoprotein B versus non-high-density lipoprotein cholesterol: is the debate really over? Eur J Prev Cardiol. 2022;29:2372–3.
doi: 10.1093/eurjpc/zwac261
pubmed: 36348516
Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PWF, D’Agostino RB, Vasan RS. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776–85.
doi: 10.1001/jama.298.7.776
pubmed: 17699011
Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol. 2006;98:1047–52.
doi: 10.1016/j.amjcard.2006.05.024
pubmed: 17027569
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.
doi: 10.1093/eurheartj/ehab484
pubmed: 34458905
Wong ND, Budoff MJ, Ferdinand K, Graham IM, Michos ED, Reddy T, Shapiro MD, Toth PP. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. Am J Prev Cardiol. 2022;10:100335.
doi: 10.1016/j.ajpc.2022.100335
pubmed: 35342890
pmcid: 8943256
Stettler C, Suter Y, Allemann S, Zwahlen M, Christ ER, Diem P. Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. J Intern Med. 2006;260:272–80.
doi: 10.1111/j.1365-2796.2006.01690.x
pubmed: 16918825
Dron JS, Hegele RA. Genetics of Lipid and Lipoprotein Disorders and Traits. Curr Genet Med Rep. 2016;4(3):130–41.
doi: 10.1007/s40142-016-0097-y
pubmed: 28286704
pmcid: 5325854
Domanski MJ, Tian X, Wu CO, Reis JP, Dey AK, Gu Y, Zhao L, Bae S, Liu K, Hasan AA, Zimrin D, Farkouh ME, Hong CC, Lloyd-Jones DM, Fuster V. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. J Am Coll Cardiol. 2020;76(13):1507–16.
doi: 10.1016/j.jacc.2020.07.059
pubmed: 32972526
Kastelein JJP, Reeskamp LF, Hovingh GK. Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans. J Am Coll Cardiol. 2020;75(20):2567–9.
doi: 10.1016/j.jacc.2020.03.058
pubmed: 32439006
Futema M, Taylor-Beadling A, Williams M, Humphries SE. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139.
doi: 10.1016/j.jlr.2021.100139
pubmed: 34666015
pmcid: 8572866
Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214–25.
doi: 10.1038/ncpcardio0836
pubmed: 17380167
Taylor A, Wang D, Patel K, Whittall R, Wood G, Farrer M, Neely RD, Fairgrieve S, Nair D, Barbir M, Jones JL, Egan S, Everdale R, Lolin Y, Hughes E, Cooper JA, Hadfield SG, Norbury G, Humphries SE. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet. 2010;77(6):572–80.
doi: 10.1111/j.1399-0004.2009.01356.x
pubmed: 20236128
Imran M, Bhoyar RC, Jain A, et al. Genetic epidemiology of monogenic dyslipidemia and statin-associated adverse drug phenotypes in Indian population from whole-genomes of 1029 self-declared healthy individuals[J]. Human Gene. 2024;39:201252.
doi: 10.1016/j.humgen.2023.201252
Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021;77:1439–50.
doi: 10.1016/j.jacc.2021.01.027
pubmed: 33736827
Li H, Wang B, Mai Z, Yu S, Zhou Z, Lu H, Lai W, Li Q, Yang Y, Deng J, Tan N, Chen J, Liu J, Liu Y, Chen S. Paradoxical Association Between Baseline Apolipoprotein B and Prognosis in Coronary Artery Disease: A 36,460 Chinese Cohort Study. Front Cardiovasc Med. 2022;9:822626.
doi: 10.3389/fcvm.2022.822626
pubmed: 35146010
pmcid: 8821163
Johannesen CDL, Langsted A, Mortensen MB, Nordestgaard BG. Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study. BMJ. 2020;371:m4266.
doi: 10.1136/bmj.m4266
pubmed: 33293274
pmcid: 7722479
Cheng Q, Liu X-C, Chen C-L, Huang Y-Q, Feng Y-Q, Chen J-Y. The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension. Front Cardiovasc Med. 2021;8:707701.
doi: 10.3389/fcvm.2021.707701
pubmed: 34336961
pmcid: 8316599
Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA, Cannon RO3. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 1999;99:354–60.
doi: 10.1161/01.CIR.99.3.354
pubmed: 9918521